Journal article
First-line Treatment Selection for Advanced Hepatocellular Carcinoma
Abstract
The treatment landscape of advanced/unresectable hepatocellular carcinoma (uHCC) has rapidly evolved since 2018. Over recent years, various systemic therapies and treatment approaches have been explored. Systemic therapy has primarily relied on tyrosine kinase inhibitors (TKIs); however, immune checkpoint inhibitors (ICIs) have more recently entered the realm of the treatment armamentarium.
Authors
Al Maqrashi Z; Meyers BM
Journal
Canadian Oncology Today, , ,
Publisher
Catalytic Health
DOI
10.58931/cot.2024.1325
ISSN
2818-1131